Vascular endothelial growth factor (VEGF) expression in induction phase chemotherapy of acute lymphoblastic leukemia
Abstract
Background Leukemia is a hematolymphoid malignancy originating from bone marrow. The progression of hematolymphoid malignancies depends on new formation of vasculature, called angiogenesis. Angiogenesis is regulated by vascular endothelial growth factor (VEGF), which is secreted by paracrine and autocrine signaling mechanisms.
Objective To evaluate VEGF expression in induction phase chemotherapy of acute lymphoblastic leukemia (ALL) patients.
Methods This prospective, cohort study was conducted in ALL patients admitted to Dr. Wahidin Sudirohusodo Hospital, Makassar, South Sulawesi, from October 2016 to October 2017. Subjects’ VEGF levels were measured at diagnosis and at the end of induction chemotherapy.
Results VEGF levels were analyzed in 59 patients, 29 of whom were diagnosed with standard risk ALL and 30 patients with high risk ALL. VEGF levels were significantly decreased after induction phase chemotherapy in standard risk ALL and in high risk ALL subjects. There was no significant difference in VEGF levels before induction phase chemotherapy between the standard and high risk groups (P=0.405). There was also no significant difference in VEGF levels after induction phase chemotherapy between the two risk groups (P=0.094).
Conclusion The VEGF level is significantly lower after ALL induction phase chemotherapy in both the standard risk and high risk ALL groups. However, there are no significant differences in VEGF levels between the standard and high risk groups before as well as after induction phase chemotherapy.
References
2. Terwillinger T, Abdul-Hay M. Acute Lymhoblastic Leukemia : a comprehensive review and 2017 update. Blood Cancer J. 2017;7:e577.
3. Schneider P, Dubus I, Gouel F, Legrand E, Vannier JP, Vasse M. What role for angiogenesis in childhood acute lymphoblastic leukaemia? Adv Hematol. 2011;2011:274628.
4. Kresno SB. Angiogenesis. In : Ilmu Dasar Onkologi. 3th ed. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia;. 2012. p 344-68.
5. Sukhramani PS, Suthar MP. VEGF inhibitors for cancer therapy. Int J Pharmaceut Sci Drug Res. 2010;1:1-11.
6. Kalra, M, Dinand V, Choudary S, Sachdeva A, Yadav SP. Serum vascular endothelial growth factor-A levels during induction therapy in children with acute lymphoblastic leukemia. Indian Pediatr. 2013;50:659-62.
7. Peach CJ, Mignone VW, Arude MA, Alcotia DC, Hill SJ, et al. Molecular Pharmacology of VEGF-A Isoform : Binding and Signaling of VEGFR2. Int. J.Mol Sci. 2018;19(4),1264.
8. Kerbel RS. Tumor angiogenesis. New Engl J Med. 2008;358:2039-49.
9. Ribatti D. Angiogenesis as a treatment target in leukemia. Int J Hematol Oncol. 2013;2:229-42.
10. Kamima K, Gatot D, Hadinegoro S. Profil antioksidan dan oksidan pada anak dengan leukemia limfoblastik akut pada kemoterapi fase induksi (studi pendahuluan). Sari Pediatri. 2009;11:282-8.
11. Silawati T. Ridha NR, Daud D. Correlation of sex and remission of acute lymphoblastic leukemia-l1 (all-l1) in children. International Journal of Clinical and Experimental Medical Sciences. 2015;1: 11-5. DOI: 10.11648/j.ijcems.20150102.12.
12. Rogers P. Nutritional status as a prognostic indicator for pediatric malignancies. Clinical Oncolgy J. 2014;32:1293-4.
13. Mansour A, Shehata H, Ali M, Sallam M, El Khouly N, Asfour I. A novel approach to acute lymphoblastic leukemia in adults: association analysis of polymorphisms in vascular endothelial growth factor (VEGF) gene and clinical outcome. Int J Cancer Res. 2015;11:93-103.
14. Leblebisatan G, Antmen B, Sasmaz I, Kilinc Y. Vascular endothelial growth factor levels in childhood acute lymphoblastic and myeloblastic leukemia. Indian J Hematol Blood Transfus. 2012;28:24-8.
15. Giles FJ. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies. Oncologist. 2001;6:32-9.
Copyright (c) 2019 Dasril Daud, Merlyn Meta Astari, Nadirah Rasyid Ridha
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Accepted 2019-08-14
Published 2019-08-14
